Clinical Trial

TReatment for ImmUne Mediated PathopHysiology

Study acronym: TRIUMPH
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
TReatment for ImmUne Mediated PathopHysiology (TRIUMPH) is a multi-center, three arm, randomized, controlled trial of immunosuppressive therapy for children with acute liver failure. The study will determine if suppressing inflammatory responses with either corticosteroids or equine anti-thymocyte globulin therapy improves survival for children with this rare, life-threatening condition.
Protocol Amendment History 3 changes
notable Enrollment reduced: 163 -> 44 participants 2026-08-13
critical Enrollment closed, study ongoing 2026-07-29
notable Trial sites reduced: 24 -> 17 locations 2026-07-29
Trial Details
NCT Number NCT04862221
Lead Sponsor National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Collaborators: Ann & Robert H Lurie Children's Hospital of Chicago
Conditions Acute Liver Failure, Fulminant Hepatic Failure, Hepatic Encephalopathy, Acute Liver Injury, Immune Dysregulation
Enrollment 44 participants
Start Date 2022-02-09
Primary Completion 2026-08-03 (estimated)
Study Completion 2027-02 (estimated)
Updated on ClinicalTrials.gov 2026-08-12